JiangSu WuZhong Pharmaceutical Development (stock code: 600200.SH) forecasts a net profit of approximately 55 to 80 million yuan for the year 2024, turning losses into gains.
Jiangsu Wuzhong (600200.SH) released the performance forecast for the year 2024, with the company expecting to achieve a net profit...
JiangSu WuZhong Pharmaceutical Development (600200.SH) has released its performance forecast for the year 2024. The company expects to achieve a net profit attributable to the shareholders of the listed company of approximately 55 to 80 million yuan in 2024, compared to a loss in the same period last year. It is also projected to achieve a net profit attributable to the shareholders of the listed company, excluding non-recurring gains and losses, of about 35 to 60 million yuan in 2024.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
